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Polycystin-2Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by renal cyst
formation and caused by mutations in the PKD1 and PKD2 genes, which encode polycystin-1(PC-1) and -2
(PC-2) proteins, respectively. PC-1 is a large plasma membrane receptor involved in the regulation of several
biological functions and signaling pathways including the Wnt cascade, AP-1, PI3kinase/Akt, GSK3β, STAT6,
Calcineurin/NFAT and the ERK and mTOR cascades. PC-2 is a calcium channel of the TRP family. The two
proteins form a functional complex and prevent cyst formation, but the precise mechanism(s) involved
remains unknown. This article is part of a Special Issue entitled: Polycystic Kidney Disease.stic Kidney Disease.
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B.V.Published by Elsevier B.V.Excess cAMP has been suggested to play a central role in the
pathogenesis of ADPKD. Elevated cAMP appears to contribute to the
hyperproliferation of cystic epithelium by stimulating Erk1/2 via Ras
and B-Raf. Excess cAMP also drives cyst growth by activating the
cystic ﬁbrosis transmembrane conductance regulator (CFTR). Recent-
ly, a novel type-I cAMP-dependent protein kinase X (PRKX), which is
functionally distinct from protein kinase A (PKA), has been demon-
strated to play a role in ADPKD. PRKX over-expression has been
shown to stimulate the migration of human fetal collecting tubule
epithelia in culture and stimulate ureteric bud branching as well as
glomerular induction in an embryonic kidney organ culture system.
Using a viral vector gene transduction approach, PRKX has been
demonstrated to counteract the adverse effects of PKD1 mutation.
This review focuses on recent advances in our understanding of the
functions of polycystins, as well as the roles of cAMP/cAMP-
dependent kinase associated phosphorylation in the pathogenesis of
ADPKD.1. ADPKD and the polycystins
Autosomal dominant polycystic kidney disease (ADPKD) is a
genetic disorder characterized by cyst formation and progressiveenlargement of both kidneys, leading to end-stage renal disease
(ESRD) [1,2]. ADPKD has an incidence of approximately 1 in 700 live
births and is the leading cause of ESRD in the US. ADPKD is primarily
characterized by renal cysts; however, it is also a systemic disorder,
resulting in epithelial cysts in multiple organs including the liver and
pancreas [3,4]. Other clinical manifestations include hypertension,
cardiac valve abnormalities, and intracranial aneurysms [5]. Two
genes have been shown to cause ADPKD when mutated: PKD1, which
accounts for 85%, and PKD2, which is responsible for the remaining
15%. The PKD1 gene is located on chromosome 16 and encodes
polycystin-1 (PC-1) [6], whereas the PKD2 gene is located on
chromosome 4 and encodes polycystin-2 (PC-2) [7,8]. PC-1 and PC-
2 assemble through coiled-coil domains present in their intracellular
C-termini to form a functional complex, the activity of which is
required to regulate pathways that when perturbed result in renal
cystogenesis [9–12]. Most of their activities have been attributed to
the complex of PC-1 and PC-2 complex, which explains some common
symptoms observed in ADPKD1 and ADPKD2 patients [9]. However,
these two proteins also exhibit independent functions.
PC-1 is a large integral membrane glycoprotein (4303 aa, MW
~460 kDa), which includes a long N-terminal extracellular domain
(~3000 aa), 11 transmembrane domains and a short intracellular C-
terminal domain (~200 aa) [13–16]. The extracellular portion has two
leucine-rich repeats, a C-type lectin domain, 16 PKD (IgG-like)
repeats, an REJ (receptor for egg jelly) domain, and a proteolytic
GPS domain (G protein-coupled receptor [GPCR] proteolytic site) that
was shown to be functionally active[17]. The intracellular C-tail of PC-
1 contains a coiled-coil domain that is responsible for mediating
interaction with PC-2 and other proteins [10–12] and a consensus site
for interaction with heterotrimeric G proteins [18]. PC-1 has been
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proteins, suggesting that PC-1 itself might be a GPCR [17]. The C-tail
has also been shown to be cleaved at aminimum of two different sites,
generating two distinct products: a 28- to 34-kDa product containing
the entire intracellular C-tail of PC-1 (CTT) [19,20] and a second ~16-
kDa product (p112) [21]. Both of these products interact with tran-
scriptional factors β-catenin and STAT6 respectively to translocate
into the nucleus [20,21]. The extent of the cleavage of CTT and its
transcriptional activity depend on PC-2 and the regulation of
intracellular calcium stores [22].
The subcellular localization of PC-1 is controversial, partially due
to antibody speciﬁcity. However, evidence from several different
studies seems to reach a consensus on its localization to cell–cell
junctions where it modulates cell adhesion[23,24], and at sites of cell–
matrix interactions [25]. PC-1 has also been localized to the primary
cilium of renal epithelial cells, where it is thought to be involved in
ciliary mechanotransduction [26].
2. Polycystins and phosphorylation
2.1. PC-1: Phosphorylation and function
Although a growing number of studies suggest that PC-1 is asso-
ciated with several signaling pathways, the direct link of PC-1 with
phosphorylation is not well elucidated. It is an area that has received
comparatively little attention for a disease that is likely due to
defective developmental signaling. The intracellular C-tail of PC-1
contains putative phosphorylation sites. There are four tyrosines
presented, one in a consensus sequence for an SH2 domain-containing
protein binding site [28]. In addition, among the several serines and
threonines contained within this 200 amino acid portion, there are
two consensus RSSR sequences in the human protein at 4162–4167
and 4250–4253, which are consistent with target sites for phosphor-
ylation by protein kinase A (PKA) or C (PKC) [27,28]. Other putative
domains known to be involved in signaling functions include a
proline-rich sequence consistent with a putative WW site [82] and a
heterotrimeric G protein activation sequence [27]. The C-terminal of
PC-1 has been demonstrated to be phosphorylated by c-src at Y4237,
by protein kinase A at S4252, and protein kinase X (PRKX) at S4166Fig. 1. The phosphorylation sites within PC-1 and the associated signaling pathways.
The intracellular C-tail of PC-1 contains four tyrosines, one in a consensus sequence for
an SH2 domain-containing protein binding site (Y4127, YEMV). There are two
consensus RSSR sequences at 4162–4167 (RSSR1)and 4250–4253 (RSSR2), which are
consistent with target sites for phosphorylation by cAMP-dependent kinases. S4164 is
shown to be phosphorylated by PRKX and S4250 is phosphorylated by PKA. The other
putative domains known to be involved in signaling functions include a proline-rich
sequence consistent with a putative WW site (4176, PPPS). PC-1 has been shown to
regulate several signaling cascades including the Wnt cascade, AP-1, PI3kinase/Akt,
GSK3β, STAT6, the calcineurin/NFAT pathway, mTORC1 and mTORC2.[63]. These ﬁndings suggest a role for PC-1 in phosphorylation
activities and cell signaling. PC-1 has been shown to regulate several
signaling cascades in line with its role as a receptor including theWnt
cascade [20,29], AP-1 [30], PI3kinase/Akt [31,32], GSK3β [31], STAT6
[21], the calcineurin/NFAT [33] pathway, and the ERK and mTOR
cascades [34, Fig. 1]. A number of studies have demonstrated that the
PC-1 C-terminal tail associates with β-catenin and inhibits canonical
Wnt signaling, suggesting a novel mechanism through which PC1
cleavage may impact upon Wnt-dependent signaling and thereby
modulate both developmental processes and cystogenesis [20]. PC-1
has also been demonstrated to activate c-Jun N-terminal kinase and
AP-1, and this activation can bemediated by heterotrimeric G proteins
[30]. PC-1 can induce resistance to apoptosis through the phospha-
tidylinositol 3-kinase/Akt signaling pathway [31,32]. PC-1 can also
induce cell migration by regulating PI3kinase-dependent cytoskeletal
rearrangements and GSK3-β dependent cell–cell mechanical adhe-
sion [31]. In addition, studies suggested that PC-1 signaling could lead
to a sustained elevation of intracellular Ca(2+) mediated by PC-1
activation of Galpha(q) followed by PLC activation, release of Ca(2+)
from intracellular stores, and activation of store-operated Ca(2+)
entry, thus activating calcineurin and NFAT [33]. Recently, accumu-
lating evidence suggests that PC-1 might have a functional link to
mTOR signaling cascade, which regulates protein synthesis and cell
growth [34–38]. Studies have shown aberrant activation of mTOR in
several rodent models of polycystic kidney disease [35,39,40] and
treatment with rapamycin has been shown to alleviate cyst
enlargement in murine models [41–44]. Recently, Cai et al. used a
human model system to elucidate the mechanism by which PC-1
regulates the mTOR pathway and found that PC-1 modulates
phoshatidylinositol 3-kinase (PI3K)/AKT signaling to TSC2 to repress
mTOR [45]. In addition, Dere et al. [46] also demonstrated that the
intracellular C-tail of PC-1 regulates mTOR signaling by altering the
subcellular localization of the tuberous sclerosis complex 2 (TSC2)
tumor suppressor. It has been shown that phosphorylation of TSC2 at
S939 by AKT causes partitioning of TSC2 away from the membrane,
its GAP target Rheb, and its activating partner TSC1 to the cytosol
via 14-3-3 protein binding. In addition, they found that TSC2 and a
C-terminal PC-1 peptide (CP1) directly interact and that a membrane-
tethered CP1 protects TSC2 from AKT phosphorylation at S939, retaining
TSC2 at themembrane to inhibit themTOR pathway. These data identify
a unique mechanism for modulation of TSC2 repression of mTOR
signaling via membrane retention of this tumor suppressor, and identify
PC-1 as a regulator of this downstream component of the PI3K signaling
cascade. Taken together, all these ﬁndings suggest that the phosphory-
lation of PC-1 may be an important part of its function and play a
signiﬁcant role in the pathogenesis of ADPKD. However, the ligands
initiate the phosphorylation/activation of PC-1 are not well known.
Previously, immunocytochemistry, sucrose density gradient sedimenta-
tion, co-immunoprecipitation analyses and in vitro binding assays
showed that PC-1 associates with the focal adhesion proteins talin,
vinculin, p130Cas, FAK, alpha-actinin, paxillin and pp60c-src in subcon-
ﬂuent normal human fetal collecting tubule (HFCT) epithelia when cell–
matrix interactions predominate. PC-1 also forms higher S value
complexes with the cell–cell adherens junction proteins E-cadherin,
beta- and gamma-catenins in conﬂuent cultures when cell–cell interac-
tions are predominant [47,48]. In addition, using primary human kidney
epithelial cells, Roitbak et al. [49] showed the polycystins and their
associated proteins E-cadherin and β-catenin distributed in a complex
with the raft marker ﬂotillin-2, but not caveolin-1, in high-density
gradient fractions. Based on co-association of signalling molecules, such
as Src kinases and phosphatases, they proposed that the polycystin
multiprotein complex is embedded in a cholesterol-containing signalling
microdomain speciﬁedbyﬂotillin-2,which is distinct fromclassical light-
buoyant-density, detergent-resistant domains. However whether these
associated proteins are the ligands that can activate PC-1 and how they
interact with PC-1 are remained to be further studied.
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abnormalities of PC-1 and PC-2 in ADPKD can result in a down-
regulation of intracellular free calcium in renal tubular epithelium,
which in turn leads to a chronic up-regulation of cAMP [50,51].
Elevated cAMP, in the context of subnormal intracellular free calcium,
appears to contribute to the hyperproliferation of cystic epithelium by
stimulating Erk1/2 via Ras and B-Raf [52]. The activation of Erk1/2 in
cystic epithelium may be responsible for the increased activation of
mammalian target of rapamycin (mTOR), which is believed to play a
major mediating role in the hyperproliferation of cystic epithelium
[41,42,53]. cAMP excess also drives cyst growth by activating the
cystic ﬁbrosis transmembrane conductance regulator (CFTR), an ATP-
dependent chloride pump that actively extrudes chloride from cells
[54–56]. The resulting chloride gradient leads to passive efﬂux of
sodium ions as well, and this transport of sodium chloride in turn
draws water into the cyst by osmosis, causing it to progressively
expand. The increased tension on the cyst wall acts as a signal to
further boost the proliferation of cyst epithelium [57].
A central role for cAMP excess in the pathogenesis of ADPKD is
strongly suggested by the fact that decreasing adenylate cyclase
activity in cyst epithelia can inhibit the development of polycystic
kidney disease. Treatment using vasopressin receptor antagonists, or
high ﬂuid intake that suppresses vasopressin secretion, is therapeu-
tically beneﬁcial in rodent models of this disorder [35,58,59]. The role
of cAMP in the pathogenesis of ADPKD has also been further
suggested by recent ﬁndings of Yamaguchi et al. [52]. They reported
that cAMP had a mitogenic effect on epithelial cells that were derived
from ADPKD cysts but inhibited the proliferation of normal renal
epithelial cells [60,61]. To determine the mechanism underlying this
phenomenon, they demonstrated that the phenotype could be
reproduced in normal cells by altering intracellular calcium levels
and by inhibiting the PI3-K/Akt pathway, which in turn resulted in
activation of extracellular signal regulated kinase (ERK). They also
found that disruption of endogenous PC-1 function by expression of
its short C-terminus in theM1 renal collecting duct cell line resulted in
a similar up-regulation of the ERK pathway and a mitogenic response
to cAMP. These ﬁndings suggest that loss of PC-1 function may result
in changes in intracellular calcium and cAMP level, down-regulation
of PI3-K-Akt activity, and activation of ERK in ADPKD cysts, which
could lead to the development of ADPKD phenotype.
In vitro kinase studies conﬁrmed that S4252 and S4166 are phos-
phorylation site for PKA and protein kinase X (PRKX), respectively,
Y4127 for focal adhesionkinase (FAK) andY4237 for c-src [18,28,62–65].
However, the ligands phosphorylate PC-1 remained unclear. cAMP and
cAMP-dependent kinases are involved in the regulation ofmany cellular
phosphorylation events andmultiple signaling pathways includingWnt
cascade, AP-1, PI3kinase/Akt , GSK3β, STAT6, ERK and mTOR cascades
[66–69], which are found to be abnormally modulated in ADPKD.
Whether the alteration of cAMP in ADPKD is responsible for the de-
regulation of these signaling pathways remains to be studied.
2.2. PC-2: Phosphorylation and function
The function of PC-2 is less understood than PC-1. A number of
studies suggested that PC-2 is the prototypical member of a subfamily
of the TRP Ca2+ channel superfamily that is highly conserved in
metazoan evolution [7] and functions as a non-selective cation
channel [70–72]. PC-2 has also been suggested a putative role for
interaction with PC-1 in a large multiprotein complex [11]. However,
functional data in normal cells that express endogenous PC-2 are
lacking.
PC-2 is predicted to have at least four serine/threonine phosphor-
ylation sites in its cytoplasmic COOH terminus [7]. Koulen et al.
reported that PC-2 is constitutively phosphorylated at Ser812 in vivo
[73]. Phosphorylation at this site does not affect the subcellular lo-
calization or the interaction with PC-1. However, single channelstudies show that loss of phosphorylation at Ser812 results in a sig-
niﬁcant decrease in the sensitivity of the PC-2 channel to calcium
stimulation. These ﬁndings indicate that phosphorylation of PC-2 is an
important factor in regulating the activity of the channel in vivo.
Another study showed that PC-2 can activate AP-1-dependent gene
transcription via c-Jun terminal kinase and mitogen-activated protein
kinase, and that this can be modulated by the calcium-independent
PKC epsilon [74]. Furthermore, PKD2 has been shown to interact with
Hax-2, a protein that forms links with the actin cytoskeleton [75].
All this evidence implicates that PC-2 is of signaling transduction
potential.3. ADPKD and protein kinase X (PRKX)
Recently a novel type-I cAMP-dependent protein kinase X (PRKX)
has been demonstrated to play a role in ADPKD. PRKX was identiﬁed
as a serine/threonine kinase gene on the X chromosome at Xp22.3
[62,76,77]. It was abundantly expressed in fetal kidneys during kidney
organogenesis but signiﬁcantly decreased in adult kidneys. Although
the catalytic domain of PRKX has signiﬁcant homology (56.6%
identity) to human PKA-α, it is more closely homologous toDrosophila
melanogaster DC2 (65.5%) and D. discoideum PKA-C (KAPC-DICDI)
(59.6%). The aligned PRKX and PKA catalytic domains showed ex-
tensive conservation of sequence in multiple regions. However,
several residues crucial for speciﬁc binding of the regulatory (R)
subunit to the catalytic subunit were not conserved in the PRKX
family, which might contribute to the reduced binding afﬁnity of the
RI regulatory subunit to PRKX in comparison to PKA [Fig. 2, 78–81].
Several studies had shown that KAPC-DICDI plays an important role in
the development of Dictyostelium discoideum, notably in morphoge-
netic cell migration [82,83] as well as in transcriptional regulation of
cellular differentiation [82–85]. These ﬁndings implied that PRKX
might also have a role in the regulation of morphogenesis in higher
eukaryotes. Previously we showed that expression of the PRKX kinase,
but not the PKA kinase, strongly activates cellular morphogenesis and
drives the formation of epithelial tubular structures in vitro associated
with a stimulation of cellular migration [62]. We also found that PRKX
mRNA was broadly expressed in mesoderm-derived tissues in the
fetus and that expression of PRKX stimulates the migration of human
fetal collecting tubule (HFCT) epithelia in culture. Using an embryonic
kidney organ culture system that recapitulates early kidney develop-
ment in vitro and a newly developed technique for viral vector gene
transduction by microinjection into ureteric bud epithelial cells, we
demonstrated that PRKX kinase expression stimulates two distinct
aspects of renal development: Ureteric bud branching and induction
of glomeruli. These results suggest that PRKXmight play an important
role during normal kidney development and that persistent activation
of this kinase may have important effects on the abnormal cystic
tubular phenotype found in ADPKD [86,87].
The possibility of functional interactions between PC-1 and PRKX
was suggested by the renal co-distribution of PRKX and PC-1 and the
binding and phosphorylation of the C-terminal of polycystin-1 by
PRKX at S4166 in vitro. Early consequences of PKD1mutation include
increased tubule epithelial cell–matrix adhesion, decreased migra-
tion, reduced ureteric bud branching and aberrant renal tubule
dilation. PRKX has been demonstrated to counteract the adverse
effects of PKD1 mutation. We found that expression of constitutively
active PRKX in human ADPKD epithelial cell lines can rescue the
characteristic adhesion and migration defects. In addition, the co-
injection of constitutively active PRKX with inhibitory pMyr-EGFP-
PKD1 into the ureteric buds of mouse embryonic kidneys in organ
culture resulted in restoration of normal branching morphogenesis
without cystic tubular dilations [63]. These results suggest that PRKX
can restore normal function to PKD1-deﬁcient kidneys and have
implications for the development of preventative therapy for ADPKD.
Fig. 2. Sequence alignment of PKA and PRKX family members. (A) Conserved residues of kinase domains I, II, III, VIb, VII, and VIII (horizontal lines) of the catalytic core domain (10,
the PKA β-strands β2, β3, β7, β8, and β9 (ﬁlled arrows), the α-helices B, C, and D (double lines), and the PKA T197 autophosphorylation site are shown. The PRKX residues (G92,
N140, and D199), which differ from PKA residues involved in RI subunit binding, are indicated by asterisks; PKA substrate P+1 recognition residues L198, P202, and L205 (domain
VIII) are designated by small, ﬁlled pentagons. (B) C-terminal region alignments for PRKX and PKA families are shown with the large and small lobe anchor and C-terminal gate of
PKA designated. Regions of conservation within the PRKX family shared with the PKA family are designated by the consensus sequences PxxP and GDtsNF.
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WWdomainbinding sites phospho-SP/-TPandPPxY. TheWWdomain is
one of the most versatile protein–protein interaction modules that are
involved in awide varietyof cellularprocesses, includingubiquitination,
nuclear signaling, cell cycle control, regulation of cell adhesion and
migration, transcriptional regulation, and the recruitment of signaling
proteins [88–92]. Membrane-binding analyses showed strong binding
of PRKX to three proteins, Pin-1,Magi-1 and Bag-3, particularly through
the phospho-SP/-TP site in vitro. Pin-1, Magi-1, and Bag-3 have been
implicated in a variety of cellular processes, including proliferation,
apoptosis, development, differentiation, and tumorigenesis [93–96]. Co-
expression analysis conﬁrmed thepotential physiological signiﬁcance of
these interactions by localization of PRKX, Pin-1, Magi-1, and Bag-3 in
ureteric bud-derived human fetal collecting tubule epithelia in vivo and
in vitro. Cell-free in vitro studies have shown that PRKX is capable of
phosphorylating Pin-1, Mag-1, and Bag-3 [87]. The mechanism(s)
through which PRKX rescues the adhesion and migration defects of
ADPKD epithelial cells and partially restores the normal function to
PKD1-deﬁcient kidneys in culture is not clear. It is of great signiﬁcance to
further investigate the interaction of PRKX with PC-1, Pin-1, Magi-1,
Bag-3 as well as its role in the regulation of other signaling pathways
including PI3kinase/Akt, GSK3β, ERK and mTOR cascades in ADPKD cell
and animal models.
Since PRKX is a member of an ancient family of cAMP-dependent
serine/threonine kinases distinct from the classical PKA, but with
greater homology with KAPC-DICDI, it is plausible that PRKX might
share unique functions not conserved in PKA genes. A number ofstudies supported this notion by demonstrating functional differences
between PRKX and PKA. Zimmermann et al. showed that PRKX is a
novel, type-I cAMP-dependent protein kinase that is activated at
lower cAMP concentrations than the holoenzyme of PKA [97]. We
also found that PRKX activates renal epithelial cell migration and
morphogenesis, which is a role not shared with PKA [62]. Most
recently, PRKX has been demonstrated to play a stimulatory role in
angiogenesis and in contrast, PKA resulted in an inhibitory effect on
HUVEC tube formation in Matrigel (data not published yet), which
further supports that PRKX is functionally distinct from PKA although
they both are cAMP-dependent kinases. Based on these ﬁndings, we
suggest that PRKX and PKA play different roles in the mechanisms
whereby cAMP excess leads to the pathogenesis of ADPKD.
4. Conclusions
Taken together, published and recent results show that the C-
terminal of PC-1 can be phosphorylated by c-src, protein kinase A and
protein kinase X (PRKX). PC-1 has been demonstrated to regulate
several signaling cascades including the Wnt cascade, AP-1, PI3kinase/
Akt, GSK3β, STAT6, the calcineurin/NFAT pathway, and the ERK and
mTOR cascades. These ﬁndings suggest an important role for PC-1 in
phosphorylation activities and cell signaling. PC-2 is predicted to have at
least four serine/threonine phosphorylation sites in its cytoplasmic
COOH terminus and has been shown to be constitutively phosphory-
lated at Ser812 in vivo. PC-2 is likely of signaling transduction potential
since it has been reported to activate AP-1-dependent gene
1223X. Li / Biochimica et Biophysica Acta 1812 (2011) 1219–1224transcription via c-Jun terminal kinase and mitogen-activated protein
kinase. An important role for cAMPexcess in the pathogenesis of ADPKD
has recently been demonstrated. However, whether the alteration of
cAMP in ADPKD contributes to the de-regulation of the signaling
pathways abnormally modulated in ADPKD remains to be further
studied. PRKX, a cAMP-dependent kinase that exhibits distinct function
from PKA, is found to play roles during normal kidney development and
that persistent activation of this kinase may have important effects on
the abnormal cystic tubular phenotype found inADPKD.Our view is that
polycystins are essentially required to regulate important signaling
pathways related to kidney development, andwhen perturbed result in
renal cystogenesis leading to ADPKD. Protein kinases and phosphory-
lation may play an important role in the regulation of PC-1 and PC-2, as
well as the associated signaling pathways.Acknowledgments
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